看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯，血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。7 D: ?& S. q% s5 F3 r. {) T& c/ A
- ^5 a3 K# r& x8 V% B
! i' m0 H1 }' pCurrently available feasibility data for possible combination strategies.
1 W6 S) {7 j" w8 o————————————————————————————————) r% p* e, C7 s0 S0 z
Combination Feasibility according to preliminary data # R! Q) N4 W- y; R7 A; K
——————————————————————————————————5 D, K" Z! E# h! g1 O5 s$ I
Bevacizumab + sorafenib Yes, reduced dose
. b, m. m: G2 f5 C- gBevacizumab + sunitinib† No
9 H- {/ H9 M2 ~Bevacizumab + temsirolimus Yes
$ A5 j1 B% \$ K1 K8 K/ O: XBevacizumab + everolimus Yes
6 I; [; ]! j i( B( A! ~1 w# o2 vSorafenib + sunitinib ?
3 q; B0 F- L* Z6 ?4 B$ g7 W" DSorafenib + temsirolimus Yes, reduced dose ' t# v' E# Q+ h0 Q
Sorafenib + everolimus Yes, reduced dose
) Q# S6 q+ o' T1 T# o$ {( fSunitinib + temsirolimus† No
5 M, X0 x/ V4 t! wSunitinib + everolimus ?
3 _1 ^- ^2 B2 Q. d# _) g# E( KTemsirolimus + everolimus ?
8 Q/ p$ q9 P/ K {" A————————————————————2 D7 K- d* {" J; i/ Y7 _, {3 u9 R
†Led to US FDA warning.
Y! u: E7 [( d6 Y0 u7 d" Q1 O?: As yet unattempted combination.
; k) x3 b4 \: m. d$ o |
显身卡
